Context Lysiphyllum strychnifolium (Craib) A. Schmitz (LS) (Fabaceae) has traditionally been used to treat diabetes mellitus. Objective This study demonstrates the antidiabetic and antioxidant effects of aqueous extract of LS leaves in vivo and in vitro . Materials and methods The effects of aqueous LS leaf extract on glucose uptake, sodium-dependent glucose cotransporter 1 (SGLT1) and glucose transporter 2 (GLUT2) mRNA expression in Caco-2 cells, α-glucosidase, and lipid peroxidation were evaluated in vitro . The antidiabetic effects were evaluated using an oral glucose tolerance test (OGTT) and a 28-day consecutive administration to streptozotocin (STZ)-nicotinamide (NA)-induced type 2 diabetic mice. Results The extract significantly inhibited glucose uptake (IC 50 : 236.2 ± 36.05 µg/mL) and downregulated SGLT1 and GLUT2 mRNA expression by approximately 90% in Caco-2 cells. Furthermore, it non-competitively inhibited α-glucosidase in a concentration-dependent manner with the IC 50 and K i of 6.52 ± 0.42 and 1.32 µg/mL, respectively. The extract at 1000 mg/kg significantly reduced fasting blood glucose levels in both the OGTT and 28-day consecutive administration models as compared with untreated STZ-NA-induced diabetic mice ( p < 0.05). Significant improvements of serum insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and GLUT4 levels were observed. Furthermore, the extract markedly decreased oxidative stress markers by 37–53% reduction of superoxide dismutase 1 (SOD1) in muscle and malondialdehyde (MDA) in muscle and pancreas, which correlated with the reduction of MDA production in vitro (IC 50 : 24.80 ± 7.24 µg/mL). Conclusion The LS extract has potent antihyperglycemic activity to be used as alternative medicine to treat diabetes mellitus.

Lysiphyllum strychnifolium (Craib) A. Schmitz (LS, Fabaceae) is one of the folklore medicines in Thailand. The previous studies have demonstrated several pharmacological activities and high polyphenolic substances possessed by this plant. However, the suitable encapsulation of LS extract has not been discovered. This study aimed to develop LS microcapsules using spray-drying technique with pectin as a carrier. Moreover, the powder analysis and characterization were also conducted. The effects of inlet temperatures (80, 100, and 120°C) and carrier concentrations (1, 5, and 10 %w/v) on the encapsulation yield (EY), encapsulation efficiency (EE), total phenolic content (TPC), and main markers (trilobatin and yanangdaengin) of LS microcapsules were studied. Finally, the characterization was investigated by Fourier transform infrared (FTIR), X-ray diffraction (XRD), differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). The obtained results indicated that S2 microcapsule formulation, pectin to extract ratio 10:1 (w/w) at inlet temperature of 100°C, was chosen as the optimal condition because of the positive tendency to acquire higher EE as pectin level was increased. On the contrary, the level of TPC and markers was reduced due to the more addition of pectin. The FTIR, XRD, and DSC results suggested that the well-encapsulated microcapsules were obtained for S2 formulation and SEM represented the semi-spherical structure of its microstructures. The development of LS microcapsules with the proximity to gain the advantageous powder analysis and characteristic has been achieved. Therefore, this approach could be used for the subsequent manufacturing of LS extract.

Context: Triphala is a traditional herbal formulation consisting of dried fruits from three plants namely, Terminalia bellirica, Terminalia chebula and Phyllanthus emblica. Its traditional used to treat many ailments, including various types of cancers, health promotion, and longevity. Aims: To evaluate the ability of an aqueous extract Triphala (TPL) to inhibit the growth of Hepatocellular carcinoma cells (HepG2) and in mice. Methods: The anticancer activity of TPL and its composite extracts was assessed in vitro by MTT assay with HepG2 cells. The mice were inoculated with HepG2 cells and then divided randomly into six groups (6 mice/group): control group, positive control group (intraperitoneal with 3 mg/kg body weight doxorubicin), and TPL treatment groups (oral administrated with 50, 100, and 200 mg/kg body weight TPL, respectively). Anticancer activity based on body weight, tumor growth volumes, survival time, relative organ weight, and hematological parameters was determined after administrating the TPL for 14 consecutive days. Results: The results demonstrated that the TPL extract exhibited antiproliferative activity against HepG2 cells in a time-dependent manner of treatment. The selectivity index (SI) showed that TPL is highly selective (SI>3) against the HepG2 cell line and has no activity against non-tumor cells. Oral administration with TPL extract at the dose of 200 mg/kg body weight inhibited tumor growth volume and increase the survival time. No abnormality of hematological parameters, relative organ weight, body weight, and morphology of organs were observed. Conclusions: The TPL extract at the test doses was a non-toxic drug. Our finding reveals the anticancer efficacy of TPL extract.

No abstract